A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study

Recruiting

Phase 3

YSBP vs. LUMIGANA Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study

Sponsor:

YS Life Science Co., Ltd.

Code:

NCT07661329

Conditions

Primary Open Angle Glaucoma (POAG)

Ocular Hypertension (OH)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bimatoprost ophthalmic solution 0.01% YSBP

bimatoprost ophthalmic solution 0.01% (Lumigan®)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-28. This information was provided to ClinicalTrials.gov by YS Life Science Co., Ltd. on 2026-06-22.